Tasmina Hydery of Cencora Talks Collaborative Approach to Boost Uptake of HUMIRA Biosimilars | Asembia 2024
Tasmina Hydery, Pharm.D., MBA, associate director, digital solutions, Cencora, spoke with MHE editors about the slow uptake of HUMIRA biosimilars despite there being 10 approved options on the market.
Tasmina Hydery, Pharm.D., MBA, spoke with MHE editors about the slow uptake of HUMIRA biosimilars despite there being 10 approved options on the market.
Hydery stressed the need for a collaborative effort among various stakeholders including manufacturers, providers, distributors and regulators to increase adoption. She also mentioned recent positive developments such as CVS Health's decision to remove HUMIRA from its international formularies and the VA's preference for an adalimumab biosimilar on their national formulary.
She suggests that time and energy investment are crucial for change to occur, as contracts between stakeholders are implemented post-approval. She also noted the importance of pricing in contracting decisions, with net price being particularly significant.
Additionally, Hydery discussed the value of pre-approval planning for manufacturers.
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
